Angiogenesis plays an important role in the biology of tumour progression and therapies that target the vascular endothelial growth factor (VEGF) pathways -ligands, receptors and co-receptors -have become an important treatment for many types of cancer. Bevacizumab, a monoclonal antibody against VEGF, was explored in several randomised Phase III studies conducted in patients with metastatic breast cancer. However, despite bringing improvements in progression-free survival, the use of bevacizumab has not been associated with improvements in overall survival. Further improvements in predictive biomarkers and the development of biology-driven Phase II trials will be critical to help us understand which patients would benefit the most from anti-angiogenic therapy.
Breast cancer continues to be a very prevalent disease worldwide. It is estimated that more than 39,000 women died of breast cancer in the US in 2011. 1 Advances in the treatment of early-stage disease, including screening programmes for breast cancer detection and adjuvant systemic therapies, have improved outcomes for patients.
Despite these improvements, however, many women ultimately develop metastatic breast cancer (MBC), which is essentially an incurable disease. The prognosis of patients with MBC has changed little over the past decade; the majority of patients succumb to their disease within two years of diagnosis. [2] [3] [4] Novel treatments for patients with MBC are needed to improve the control of disease and prevent symptoms while minimising toxicity.
Role of Angiogenesis in Cancer Biology
In 1970, Folkman postulated that tumour progression might be dependent on angiogenesis -the formation of new blood vessels. 5 The hypothesis was that a tumour cannot grow without blood supply and that, therefore, the inhibition of angiogenesis would be an important treatment for all cancers.
Angiogenesis is an important natural process of new blood vessel formation that occurs in the body, both in health and in disease. 6 The generation and growth of solid tumours depend on an intact vascular supply, which is stimulated by several pro-angiogenic factors.
Changes in the finely balanced equilibrium between angiogenic stimulators and inhibitors that regulate angiogenesis are linked to a broad range of angiogenesis-dependent diseases, including both cancer and non-neoplastic diseases. 7 Angiogenesis is now recognised as one of the key steps in the pathogenesis of cancer, regulating several events required for tumour development, invasion and metastasis. 8, 9 One of the most important molecules to stimulate angiogenesis is the vascular endothelial growth factor (VEGF). Moreover, VEGF has autocrine pro-survival effects on tumour cells, protecting them from stresses such as hypoxia, chemotherapy and radiotherapy. This fundamental mechanism in biology describes a multi-step process of new blood vessel formation from existing vasculature, and it is tightly regulated by pro-angiogenic factors involving autocrine and paracrine signalling. 10 To grow and obtain more blood, tumours exert multiple strategies to create or stimulate the formation of blood vessels, including sprouting angiogenesis, vessel co-option, intussusception of existing vessels and recruitment of bone marrow-derived endothelial progenitor cells into growing vessels.
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VEGF is essential for the development of neovasculature in the early stages of tumourigenesis and is thought to play a key role in tumour metastasis. The transition of a tumour from the 'avascular'
or 'prevascular' phase to the 'vascular' phase (increased growth
Can Discontinuation of Anti-angiogenic Therapy Lead to Cancer Rebound?
Recently, two preclinical studies suggested that the discontinuation of anti-VEGF pathway inhibition can cause tumour progression. 15, 16 There is also clinical evidence that certain solid tumours can regrow during 'drug holidays' or in patients treated with anti-VEGF monotherapy for renal cell carcinoma. 17 This 'rebound effect' has led to speculation that the more rapid disease progression after 6 These mechanisms include:
• ligand sequestration;
• external receptor blocking;
• internal receptor blocking (tyrosine kinase inhibitors); and
• inhibition of the VEGF receptor message. 6 Bevacizumab has been the most studied agent in the field of angiogenesis in multiple cancer types. 22 An experimental study
showed that bevacizumab neutralised all isoforms of human VEGF with a dissociation constant of 1.1 nmol/l. 23 Another study showed showed that bevacizumab was safe and could be combined with chemotherapy without apparent additional toxicity. 24, 26, 27 Based on the results of these studies, Phase III randomised trials have been undertaken to evaluate the role of the drug as first-line therapy in women with MBC. These studies are summarised in Table 1 .
The first was a randomised Phase III trial of capecitabine alone compared with bevacizumab plus capecitabine in a group of heavily pre-treated breast cancer patients. 28 Patients who received the combination therapy had a superior overall response rate (ORR).
However, this did not translate into longer PFS and OS, and quality of life was comparable in both treatment groups.
The second was the Eastern cooperative oncology group E2100
study, an open label, Phase III randomised clinical trial in which bevacizumab was added to weekly paclitaxel chemotherapy as first-line therapy for MBC. 29 The primary endpoint was PFS, which was significantly longer in patients who received the drug combination than in those who received paclitaxel alone. There was also a significant improvement in the ORR. However, despite the improvement in PFS by more than a mean 5. The AVADO trial was a Phase III placebo-controlled, randomised study of two doses of bevacizumab (7.5 mg/kg or 15 mg/kg every three weeks) with or without docetaxel (100 mg/m 2 every three weeks) as first-line therapy for patients with recurrent breast cancer or MBC. 30 A longer PFS interval was observed with docetaxel plus bevacizumab at both doses compared with docetaxel alone. The ORR was highest with docetaxel plus bevacizumab at 15 mg/kg.
However, there was no statistically significant difference in OS duration between treatment groups. The study showed that the addition of bevacizumab at a dose of 15 mg/kg to docetaxel resulted in a significant increase in PFS.
RiBBON-1 was a randomised, double-blind, placebo-controlled trial.
Patients were randomised in a 2:1 ratio to receive either bevacizumab (15 mg/kg every three weeks) in addition to standard first-line chemotherapy by physician choice, or placebo plus chemotherapy, as first-line treatment for MBC. 31 The PFS and ORR were superior for the group treated with bevacizumab, regardless of the standard chemotherapy regimen used. There were no statistically significant differences in OS and one-year survival rates. The toxicity profiles were similar to those seen in other trials using bevacizumab.
Is Overall Survival the Most Important Endpoint in Metastatic Breast Cancer Patients?
This lack of OS benefit and the relatively inferior results of the confirmatory trials 30, 31 created uncertainty regarding the utility of bevacizumab in MBC. When observing different outcomes in clinical trials with similar designs, it is essential to examine the potential causes of such differences. In this case, one of the points to consider is the type and schedule of chemotherapy that were used in the E2100 trial. Weekly paclitaxel is superior to three-weekly paclitaxel; it led to a doubling of time to progression and pathological complete response in patients with metastatic and early-stage breast cancer, respectively. 32 Furthermore, the good tolerance of this regimen allows patients to receive multiple cycles, which is not the case with the maximum doses of docetaxel or anthracycline-based regimens. Thus, the success of combining VEGF-targeted therapies and chemotherapy may not be random, but is likely to depend on the type of chemotherapy used. 33 Another important point to consider is the trial design and how it can impact the interpretation of OS outcomes. Studies that give patients the possibility to cross over upon progression cannot accurately report OS, given that a significant proportion of patients will receive bevacizumab at some point in their treatment, either as first-or as second-line therapy. Indeed, the AVADO and RiBBON-1 trials had a high percentage of post-progression cross-over rates. Adding to the controversy, further results of the AVEREL study were recently reported and showed that adding bevacizumab to standard therapy prolongs PFS by about three months in women with HER2-positive locally recurrent or metastatic breast cancer. 25 This benefit of added bevacizumab was similar across most subgroups, except among patients aged 65 years or older and those with measurable disease, in which the benefit was greater. The ORR was significantly higher in the bevacizumab group.
Conclusions and Future Directions
Anti-angiogenic therapy that targets VEGF or its receptors has become a mainstay of therapy in patients with glioblastoma or colorectal, lung, kidney or ovarian cancer. In the last 10 years, more than 2,000 trials have been conducted with agents that target the VEGF pathway. 43 In contrast with the enthusiasm for VEGF-targeted growth factor genes -including VEGF -were greater in adjacent normal tissues than in the primary tumour tissue. 44 The authors concluded that primary breast tumours are not a site of active angiogenesis. The role of pro-and anti-angiogenic factors in metastatic tissues needs to be elucidated.
One remarkable difference with other targeted therapies is that angiogenesis is an ubiquitous target. Furthermore, preclinical data suggest that the tumour vasculature is not the same in all cases and that there are molecular differences in tumour endothelial cells from a variety of tumours. 45, 46 Because of the lack of reproduction of the E2100 trial results, the 5.5 month improvement in PFS demonstrated by that trial has been interpreted by some authors as an outlier. 47 The limited success of anti-angiogenic therapy in breast cancer highlights the need for continued basic science investigation and clinical trials. The type of study design and how we measure success will be critical for the next generation of clinical trials using anti-VEGF therapy. n
